PV Bulletin

Regulatory Changes in Pharmacovigilance Data Management Following EMA's ISG Meeting

The 17th Industry Standing Group (ISG) meeting discussed significant updates affecting the management and exchange of pharmacovigilance data, including signal management and electronic reporting.

Primary source: View

PV Impact Brief

Urgency: HighConfidence: high

What changed

EMA announced procedural and technical changes affecting how MAHs manage and exchange pharmacovigilance data, specifically regarding signal management and electronic reporting through EMA platforms, as discussed during the ISG meeting on June 29, 2026.

Why it matters

These changes are foundational for improving the efficiency of regulatory submissions and enhancing the quality of pharmacovigilance data exchanged between stakeholders.

Action needed

MAHs must align their workflows to accommodate the updated requirements for signal management and ICSR submissions as per the discussions in the ISG meeting.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementICSR
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Policy change details

Document type
Consultation / Forum
Policy status
consultation
Publication date
2026-06-29
Policy change
A stakeholder meeting to discuss ongoing regulatory digitalisation, SPOR data implementation, and system updates affecting procedural interactions.

Key changes

Updates on the IRIS system and SPOR (Substance, Product, Organisation, and Referential data) implementation, which are foundational for regulatory submissions in the EU.

Affected workflows

Signal ManagementICSR

Responsible groups

PV OperationsITData ManagementRegulatory Affairs

PV impact

Procedural and technical changes discussed impact how MAHs manage and exchange pharmacovigilance data, including signal management and electronic reporting through EMA platforms.

View regulator source

Source document details

Exact policy details

Meeting Date and Time
29 June 2026; 09:30-13:10 CEST
Applies to: All stakeholders involved in the ISG meeting
Agenda – 17th Industry Standing Group (ISG) meeting · p. 1 · High · Source
Chairperson
Juan Garcia Burgos
Applies to: Participants of the ISG meeting
Chair: Juan Garcia Burgos, Head of Public and Stakeholder Engagement Department · p. 1 · High · Source
Revised Pharmaceutical Legislation Update
Implementation of revised pharmaceutical legislation
Applies to: Stakeholders involved in pharmaceutical regulation
Update from the EMA on the implementation of the revised pharmaceutical legislation · p. 1 · High · Source
ePI Vaccine Roll-out
Planned for Q4 2026
Applies to: All stakeholders involved in vaccine distribution and monitoring
Roll-out ePI vaccine Q4 2026 · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 29, 2026

Full briefing

Practical implication

MAHs must align their workflows to accommodate the updated requirements for signal management and ICSR submissions as per the discussions in the ISG meeting.

The European Medicines Agency (EMA) held its 17th ISG meeting, focusing on updates to the IRIS system, SPOR data implementation, and procedural changes that will impact marketing authorization holders (MAHs) regarding pharmacovigilance data management. Changes include updated requirements for signal management and ICSR processes.

What changed: EMA announced procedural and technical changes affecting how MAHs manage and exchange pharmacovigilance data, specifically regarding signal management and electronic reporting through EMA platforms, as discussed during the ISG meeting on June 29, 2026.

Why it matters: These changes are foundational for improving the efficiency of regulatory submissions and enhancing the quality of pharmacovigilance data exchanged between stakeholders.

Practical implication: MAHs must align their workflows to accommodate the updated requirements for signal management and ICSR submissions as per the discussions in the ISG meeting.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Pharmacovigilance#Consultation / Forum#consultation#European Medicines Agency (EMA)#Reporting Requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward